8 INDUSTRY NEWS
ARDENA BUYS SYNTAGON
Contract development and manufacturing organisation (CDMO) Ardena has acquired Syntagon, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.
The acquisition, which is the
CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity and means that bigger batch sizes up to 100kg can now be handled by Ardena. Syntagon also adds specialist expertise in GMP chromatographic purification processes to the group. The announcement
follows Ardena’s acquisition of ChemConnection in March 2018 and is part of its strategy to form a leading integrated drug development company and reach the €35m sales mark this year.
New cell lines for cancer research
AMS Bio has introduced a new range of over 400 isogenic cell lines that provide a reliable and efficient alternative to traditional human disease models.
Isogenic cell lines can be used to
model any disease with a genetic foundation. Cancer is one such disease for which isogenic human disease cell line models have been widely used. The Isomax range of isogenic engineered cell line products feature diverse oncogenic driver mutations in various
Benchtop luminometer launched
Vitl Life Science Solutions has launched the Lu-mini – a new product aimed at the low-cost OEM benchtop luminometer market. The company has taken an
innovative approach in the design of the Lu-mini; putting a modern spin on the traditional analytical instruments that have been occupying valuable
bench space for decades. Tom Ackrill at Vitl Life Science Solutions, says: “We have designed a luminometer that has been engineered using the latest technologies to provide researchers with everything they need to get the job done – quickly and accurately.” The design of the sample chamber allows the use of a range of vessel sizes, including 10-15mm round vials and 10mm square cuvettes. In comparison to some other luminometers that would require additional modules to accommodate varying vessel sizes, the Lu-mini is able to hold vessels varying in shape and length without the need for additional adapters; holding the sample repeatedly in the same place during multiple insertions.
www.scientistlive.com
pathways, including the MAPK and mTOR interactive signalling pathways. Over 150+ point mutations engineered across 15+ genes are available such as MAPK pathway line diverse mutations in EGFR, KRAS and BRAF. All cell lines are available with genetically matched ‘normal cells’ to provide a toolset for enhancing our understanding of cancer biology, or for high-throughput screening to identify lead/target compounds for cancer therapeutics.
AGILENT ACQUIRES GENOHM
Agilent Technologies has entered into a definitive agreement to acquire privately held Genohm, a developer of highly differentiated, on-premise and cloud-based software solutions for laboratory management. Genohm’s main lab software
automation suite, SLIMS, is a digital platform that provides laboratories with a rapidly deployable LIMS and electronic lab notebook (ELN) environment that is used in biobanks, research labs and next-gen sequencing facilities. The platform tracks data and samples, tests and users, and results and workflows, from material shipment to the result from lab instruments and in-silico analysis pipelines.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
